


PERSONAL INFORMATION

Khaled EZZEDINE



📍 Université Paris Est Créteil (UPEC) and University Hospital Henri Mondor, Department of Dermatology, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
☎ +33 6 65 37 70 45

✉ khaled.ezzedine@aphp.fr

Sex M | Date of birth 18/06/1967 | Nationality France

EDUCATION AND TRAINING

1998: MD, Dakar, Senegal
2004: Qualified in Dermatology, Brussels, Belgium
2005: Master of sciences in Biology and Health, Bordeaux, France
2006-2008: PhD in Epidemiology, Paris, France
2013: Accreditation to supervise research, Bordeaux, France

WORK EXPERIENCE

2000-2004: Intern, University Hospital Center ERASME, Université Libre de Bruxelles, Brussels, Belgium
2005-2006: Resident, University Hospital Center Erasme, Université Libre de Bruxelles, Brussels, Belgium
2006-2008: Applicant researcher at the U557 Inserm (UMR Inserm/Inra/Cnam/Paris 13) et Unité de Surveillance et d'Epidémiologie Nutritionnelle (USEN, InVS/Cnam/Paris13), Centre de Recherche en Nutrition Humaine Ile-de-France, SMBH Paris 13 (Director, Pr Serge Hercberg).
2008-2015: Senior physician, Department of Dermatology, University Hospital Centre St-André, Bordeaux, France
2008-2015: Associate Professor of Dermatology, University Victor Segalen Bordeaux 2, Bordeaux, France and Vice-Director of the National Reference Center for Rare Skin Diseases of Bordeaux, Responsible for epidemiological research
Since 2008: Lead of the skin Group in the French national cohorts NUTRINET and SUVIMAX
2015: Elected Professor of Dermatology, Department of Dermatology University Hospital Henri Mondor and Université Paris Est Créteil (UPEC)

REFERENCED PUBLICATIONS (SELECTION OF 10 MOST SIGNIFICANT PUBLICATIONS)

1. Prey S, Voisard JJ, Delarue A, Lebbé G, Taieb A, Léauté-Labrèze C, **Ezzedine K**. Safety of propranolol therapy for severe infantile hemangiomas. *JAMA* 2016; 315(4):413-5. (IF: 35.3, Rang SIGAPS A).
2. **Ezzedine K**, Whitton M, Pinart M. Interventions for vitiligo. *JAMA* 2016; 316: 1708-1709. (IF: 37.684, Rang SIGAPS A)
3. Gan EY, Cario-André M, Pain C, Goussot JF, Taieb A, Seneschal J, **Ezzedine K**. Follicular vitiligo: A report of 8 cases. *J Am Acad Dermatol* 2016 (in press) (IF: 5.661, Rang SIGAPS A).
4. Salzes C, Abadie S, Seneschal J, Whitton M, Meurant JM, Jouary T, Ballanger F, Boralevi F, Taieb A, Taieb C, **Ezzedine K**. The Vitiligo Impact Patient scale (VIPs): development and validation of a vitiligo burden assessment tool. *J Invest Dermatol* 2016; 136: 52-8 (IF: 7.216, Rang SIGAPS A).
5. Touvier M, Deschaseaux M, Monturcy M, Sutton N, Chamaux N, Kesse-Guyot E, Assman K, Fezeu L, Latino-Martel P, Druet-Pecollo N, Guinot C, Malvy D, Latreille J, Galan P, Hercberg S, Leclerc S, Souberbielle JC, **Ezzedine K**. Determinants of 25OHD status in Caucasian adults: influence of sun exposure, dietary vitamin D intake, socio-demographic, lifestyle, anthropometric and genetic factors. *J Invest Dermatol* 2015; 135: 378-88 (IF: 7.216, Rang SIGAPS A).
6. **Ezzedine K**, Eleftheriadou V, Whitton M, Nan Geel N. Vitiligo. *Lancet* 2015; 386: 74-84. (IF: 45.217, Rang SIGAPS A).
7. **Ezzedine K** *, Dutkiewicz AD*, Mazereeuw-Hautier J, Lacour JP, Barbarot S, Vabres P, Miquel J, Balguerie V, Martin L, Boralevi F, Bessou P, Chateil JF, Léauté-Labrèze C. On behalf of the Groupe de Recherche Clinique en Dermatologie Pédiatrique. A prospective study of risk factors for leptomeningeal angiomas in children with upper facial port-wine stain. *J Am Acad Dermatol* 2015; 72: 473-80 (IF: 4.449, Rang SIGAPS A). (*Equally contributor)
8. Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, Eleftheriadou V, **Ezzedine K**. Interventions for vitiligo. *Cochrane Database Syst Rev* 2015; 2:CD003263 (IF:

6.032, Rang SIGAPS A).

9. **Ezzedine K**, le Thuaut A, Jouary T, Ballanger F, Taieb A, Bastuji-Garin S. Latent Class Analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes. *Pigment Cell Melanoma res* 2014; 27: 134-9 (IF: 4.619, Rang SIGAPS B).
10. Diallo A, Boniface K, Jouary T, Seneschal J, Morice-Picard F, Prey S, Cario-André M, Mazereeuw-Hautier J, Taieb A, **Ezzedine K**. Development and validation of the K-VSCOR for scoring Koebner's phenomenon in Vitiligo/non-segmental vitiligo. *Pigment Cell Melanoma res* 2013; 26: 402-7 (IF: 4.619, Rang SIGAPS B).

REFERENCED PUBLICATIONS (ORIGINAL ARTICLES AND RESEARCH LETTERS)

1. Phan C, **Ezzedine K**, Lai C, Le Cleach L, Cogrel O, Fardet L, Wolkenstein P, Chosidow O, Beylot Barry M, Sbidian E. Validation of self-diagnostic questionnaires for inflammatory skin disorders. *Acta Derm Venereol* 2017 (in press).
2. Jacquemin C, Rambert J, Guillet S, Thiolat D, Boukhedouni N, Doutre MS, Darrigade AS, **Ezzedine K**, Blanco P, Taieb A, Boniface K, Seneschal J. HSP70 potentiates interferon-alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. *Br J Dermatol* 2017 (in press)
3. van Geel N, Boniface K, Seneschal J, Jacquemin C, Speeckaert R, Wolkerstorfer A, Bekkenk M, Lommerts JE, Hamzavi I, Pandya A, Eleftheriadou V, **Ezzedine K**, Giannarelli D, Gnarra M, Sperduti I, Prinsen C, Harris J, Taieb A, Picardo M. Meeting report: Vitiligo Global Issues Consensus Conference (VGICC) Workshop "Outcome measurement instruments" and Vitiligo International Symposium, Rome, Nov 30-Dec 3rd. *Pigment Cell Melanoma Res* 2017 (in press)
4. Saurat JH, Mengeaud V, Georgescu V, Coutanceau C, **Ezzedine K**, Taieb C. A simple self-diagnosis tool to assess the prevalence of dermatoporosis in France. *J Eur Acad Dermatol Venereol* 2017 (in press). (IF: 3.029, Rang SIGAPS B).
5. Darrigade AS, Milpied B, Truchetet ME, Schaeverbeke T, Laharie D, Zerbib F, Beylot-Barry M, Jouary T, Taieb A, **Ezzedine K**, Seneschal J. Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF alpha Inhibitors. *Acta Derm Venereol* 2017 (in press); doi: 10.2340/00015555-2636.
6. van Geel N, Lommerts JE, Bekkenk MW, Prinsen CA, Eleftheriadou V, Taieb A, Picardo M, **Ezzedine K**, Wolkerstorfer A, Speeckaert R; international Vitiligo Score Working Group. Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES). *J Am Acad Dermatol* 2017; 76: 464-471. (IF: 5.621, Rang SIGAPS A).
7. Gan EY, Eleftheriadou V, Esmat S, Hamzavi I, Passeron T, Böhm M, Anbar T, Goh BK, Lan CE, Lui H, Ramam M, Raboobee N, Katayama I, Suzuki T, Parsad D, Seth V, Lim HW, van Geel N, Mulekar S, Harris J, Wittal R, Benzekri L, Gauthier Y, Kumarasinghe P, Thng ST, Silva de Castro CC, Abdallah M, Vrijman C, Bekkenk M, Seneschal J, Pandya AG, **Ezzedine K**, Picardo M, Taieb A; on behalf of the VGICC. Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. *Pigment Cell Melanoma Res* 2017; 30: 28-40. (IF: 4.163, Rang SIGAPS B).
8. Lommerts JE, Teulings HE, **Ezzedine K**, Van Geel N, Hartmann A, Speeckaert R, Spuls PI, Wolkerstorfer A, Luiten R, Bekkenk MW. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. *J Am Acad Dermatol* 2016; 75: 1198-1204. (IF: 5.621, Rang SIGAPS A).
9. Deschasaux M, Souberbielle JC, Partula V, Lécuyer L, Gonzalez R, Srour B, Guinot C, Malvy D, Latino-Martel P, Druesne-Pecollo N, Galan P, Hercberg S, Kesse-Guyot E, Fassier P, Touvier M*, **Ezzedine K***. What Do People Know and Believe about Vitamin D? *Nutrients* 2016; 8: pii: E718. (IF: 3.759, Rang SIGAPS B). (*Equally contributing)
10. Banner A, Dinsey M, **Ezzedine K**, Dadzie OE. The Spectrum of Skin Diseases Occurring in a Multi-Ethnic Population in Northwest London, UK; Findings of a Cross-Sectional Descriptive Study. *Br J Dermatol* 2016 (In press). (IF: 4.317, Rang SIGAPS A).
11. Mermin D, Boursault L, Milpied B, Taieb A, **Ezzedine K**, Seneschal J. DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis. *J Eur Acad Dermatol Venereol* 2016; 30: 1961-1964. (IF: 3.029, Rang SIGAPS B).
12. Laville V, Le Clerc S, **Ezzedine K**, Jdid R, Taing L, Labib T, Coulonges C, Ulveling D, Carpentier W, Galan P, Hercberg S, Morizot F, Latreille J, Malvy D, Tschachler E, Zagury JF. A Genome-Wide Association Study in Caucasian Women suggests the involvement of HLA genes in the severity of facial solar lentigines. *Pigment Cell Melanoma Res* 2016; 29: 550-8. (IF: 4.163, Rang SIGAPS B).
13. **Ezzedine K**, Whitton M, Pinart M. Interventions for vitiligo. *JAMA* 2016; 316: 1708-1709. (IF: 37.684, Rang SIGAPS A)
14. Jin Y, Andersen G, Yorgov D, Ferrara TM, Ben S, Brownson KM, Holland PJ, Birlea SA, Siebert J, Hartmann A, Lienert A, van Geel N, Lambert J, Luiten RM, Wolkerstorfer A,

- Wietze van der Veen JP, Bennett DC, Taïeb A, **Ezzedine K**, Kemp EH, Gawkrödger DJ, Weetman AP, Köks S, Prans E, Kingo K, Karelson M, Wallace MR, McCormack WT, Overbeck A, Moretti S, Colucci R, Picardo M, Silverberg NB, Olsson M, Valle Y, Korobko I, Böhm M, Lim HW, Hamzavi I, Zhou L, Mi QS, Fain PR, Santorico SA, Spritz RA. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. *Nat Genet* 2016; 48: 1418-1424. (IF: 31.616, Rang SIGAPS A).
15. Gan EY, Gahat T, Cario-André M, Seneschal J, **Ezzedine K**, Taïeb A. Clinical repigmentation patterns in Pediatric vitiligo. *Br J Dermatol* 2016; 175: 555-60. (IF: 4.317, Rang SIGAPS A).
 16. Deschaseaux M, Souberbielle JC, Sutton A, Charnaux N, Kesse-Guyot E, Latino-Martel P, Druésne-Pecollo N, Szabo de Edenleyi F, Galan P, Hercberg S, Touvier M*, **Ezzedine K***. Quick and easy screening for vitamin D insufficiency in adults: a scoring system to be implemented in daily clinical practice. *Medicine* 2016; 95: e2783. (*Equally contributor)
 17. Deschaseaux M, Souberbielle JC, Latino-Martel P, Sutton A, Charnaux N, Druésne-Pecollo N, Galan P, Hercberg S, Le Clerc S, Kesse-Guyot E, **Ezzedine K**, Touvier M. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk. *Br J Nutr* 2016 115: 305-14 (IF: 3.453, Rang SIGAPS B).
 18. Vergier B, Elodie Laharanne, Prochazkova-Carlotti M, de la Fouchardière A, Merlio JP, Avril MF, Bodemer C, Lacoste C, Boralevi F, Taïeb A, **Ezzedine K**, Fraitag S. Proliferative Nodules versus Melanoma arising in Giant Congenital Melanocytic Nevi during childhood. *JAMA Dermatol* 2016 (in press) (IF: 4.6, Rang SIGAPS A).
 19. Gan EY, Cario-André M, Pain C, Goussot JF, Taïeb A, Seneschal J, **Ezzedine K**. Follicular vitiligo: A report of 8 cases. *J Am Acad Dermatol* 2016 (in press) (IF: 5.661, Rang SIGAPS A).
 20. Deschaseaux M, Souberbielle JC, Latino-Martel P, Sutton A, Charnaux N, Druésne-Pecollo N, Galan P, Hercberg S, Le Clerc S, Kesse-Guyot E, **Ezzedine K**, Touvier M. Weight status and alcohol intake modify the association between vitamin D and breast cancer risk". *J Nutr* 2016 (in press) (IF: 3.875, Rang SIGAPS B).
 21. Whitton M, Pinart M, Batchelor JM, Leonardi-Bee J, Gonzalez U, Jiyad Z, Eleftheriadou V, **Ezzedine K**. Evidence-Based Management of vitiligo: summary of a Cochrane systematic review. *Br J Dermatol* 2016 (in press) doi: 10.1111/bjd.14356 (IF: 4.275, Rang SIGAPS A).
 22. Van Geel N, Loomerts J, Bekkenk M, Wolkerstorfer A, Prinsen S, Eleftheriadou V, Taïeb A, Picardo M, **Ezzedine K**, Speekhaert R. Development and validation of the Vitiligo Extent Score (VES): an international collaborative initiative. *J Invest Dermatol* 2015 (in press). (IF: 7.216, Rang SIGAPS A).
 23. Prey S, Voisard JJ, Delarue A, Lebbé G, Taïeb A, Léauté-Labrèze C, **Ezzedine K**. Safety of propranolol therapy for severe infantile hemangiomas. *JAMA* 2016; 315(4):413-5. (IF: 35.3, Rang SIGAPS A).
 24. Deschaseaux M, Souberbielle JC, Latino-Martel P, Sutton A, Charnaux N, Druésne-Pecollo N, Galan P, Hercberg S, Le Clerc S, Kesse-Guyot E, **Ezzedine K**, Touvier M. Prospective associations between vitamin D status, vitamin D-related gene polymorphisms and risk of tobacco-related cancers. *Am J Clin Nutr* 2015 (in press) (IF: 6.770, Rang SIGAPS A).
 25. Salzes C, Abadie S, Seneschal J, Whitton M, Meurant JM, Jouary T, Ballanger F, Boralevi F, Taïeb A, Taïeb C, **Ezzedine K**. The Vitiligo Impact Patient scale (VIPs): development and validation of a vitiligo burden assessment tool. *J Invest Dermatol* 2015 (in press) (IF: 7.216, Rang SIGAPS A).
 26. Donnenfeld M, Deschaseaux M, Latino-Martel P, Galan P, Hercberg S, **Ezzedine K**, Touvier M. Prospective association between dietary folate intake and skin cancer risk: results from the SU.VI.MAX cohort. *Am J Clin Nutr* 2015; 102: 471-8 (IF: 6.770, Rang SIGAPS A).
 27. **Ezzedine K**, Grimes PE, Meurant JM, Seneschal J, Léauté-Labrèze C, Jouary T, Taïeb C, Taïeb A. Living with vitiligo: results from a national survey indicate differences between skin phototypes. *Br J Dermatol* 2015 (in press) (IF: 4.275, Rang SIGAPS A).
 28. Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Domp Martin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Mateus C*, **Ezzedine K***. Sentinel node status and Immunosuppression: Factors of recurrence in localized Merkel Cell Carcinoma. *Acta Derm Venereol* 2015 (in press) (IF: 3.025, Rang SIGAPS A). (*Contributeur équivalent)
 29. Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, Katayama I, Anbar T, Abdallah M, Benzekri L, Gauthier Y, Harris J, Silva de Castro CC, Pandya A, Goh BK, Lan CC, Oiso N, Al Issa A, Esmat S, Le Poole IC, Lee AI, Parsad D, Taïeb A, Picardo A, **Ezzedine K**. On behalf of the Vitiligo Global Issues Consensus Group (VGICG). Developing core outcomes set for vitiligo clinical trials: International e-Delphi Consensus. *Pigment Cell Melanoma Res* 2015; 28: 363-9 (IF: 4.619, Rang SIGAPS B).
 30. Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, Eleftheriadou V, **Ezzedine K**. Interventions for vitiligo. *Cochrane Database Syst Rev* 2015; 2:CD003263 (IF: 6.032, Rang SIGAPS A).
 31. Cavalié M, **Ezzedine K**, Fontas E, Montaudié H, Castela M, Bahadoran P, Taïeb A, Lacour JP, Passeron T. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. *J Invest Dermatol* 2015; 135: 970-4 (IF: 7.216, Rang SIGAPS A).
 32. Touvier M, Deschaseaux M, Monturcy M, Sutton N, Charnaux N, Kesse-Guyot E, Assman

- K, Fezeu L, Latino-Martel P, Druesne-Pecollo N, Guinot C, Malvy D, Latreille J, Galan P, Hercberg S, Leclerc S, Souberbielle JC, **Ezzedine K**. Determinants of 25OHD status in Caucasian adults: influence of sun exposure, dietary vitamin D intake, socio-demographic, lifestyle, anthropometric and genetic factors. *J Invest Dermatol* 2015; 135: 378-88 (IF: 7.216, Rang SIGAPS A).
33. **Ezzedine K** *, Dutkiewicz AD*, Mazereeuw-Hautier J, Lacour JP, Barbarot S, Vabres P, Miquel J, Balguerie V, Martin L, Boralevi F, Bessou P, Chateil JF, Léauté-Labrèze C. On behalf of the Groupe de Recherche Clinique en Dermatologie Pédiatrique. A prospective study of risk factors for leptomeningeal angiomas in children with upper facial port-wine stain. *J Am Acad Dermatol* 2015; 72: 473-80 (IF: 4.449, Rang SIGAPS A). (*Contributeur équivalent)
 34. **Ezzedine K**, Mahé A, van Geel N, Cardot-Leccia N, Gauthier Y, Descamps V, Al Issa A, Ly F, Chosidow O, Taieb A, Passeron T. Hypochromic vitiligo: delineation of a new entity. *Br J Dermatol* 2015; 172: 716-21 (IF: 4.275, Rang SIGAPS A).
 35. Seneschal J, Boniface K, **Ezzedine K**, Taieb A. Accelerating bleaching in vitiligo: balancing benefits vs risks. *Exp Dermatol* 2015; 23: 879-80 (IF: 4.115, Rang SIGAPS A).
 36. Descamps V, Mahé E, Maccari F, Begon E, Barthelemy H, Reguiat Z, Bénétou N, Estève E, Chaby G, Ruer-Mulard M, Steiner HG, Thomas-Beaulieu D, Avenel-Audran M, Goujon-Henry C, Sigal ML, **Ezzedine K**, Beauchet A. Severe androgenetic alopecia as a proxy of metabolic syndrome in male psoriatic patients older than 59 years. *Eur J Dermatol* 2014; 24: 356-60 (IF: 1.990, Rang SIGAPS C).
 37. Dreyfus I, Bourrat E, Maruani A, Bessis D, Chiavérini C, Vabres P, **Ezzedine K**, Mazereeuw-Hautier J. Factors associated with impaired quality of life in adult patients suffering from inherited ichthyosis. *Acta Derm Venereol* 2015; 94: 344-6 (IF: 3.025, Rang SIGAPS A).
 38. Touvier M, Deschasaux M, Montourcy M, Sutton A, Charmaux N, Kesse-Guyot E, Fezeu LK, Latino-Martel P, Druesne-Pecollo N, Malvy D, Galan P, Hercberg S, **Ezzedine K**, Souberbielle JC. Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. *J Clin Endocrinol Metab* 2014; 99: 1196-203.
 39. Frascari F, Dreyfus I, Rodriguez L, Gennero L, **Ezzedine K**, Salles JP, Mazereeuw-Hautier J. Prevalence and risk factors of vitamin D deficiency in patients with inherited ichthyosis. *Orphanet J Rare Dis* 2014; 9: 127 (IF: 3.358, Rang SIGAPS B).
 40. **Ezzedine K** *, Gey A*, Diallo A, Prey S, Dreyfus I, Maza I, Mazereeuw-Hautier J, Taieb A, Léauté-Labrèze C. Stay in NICU and infantile hemangioma development. *J Eur Acad Dermatol Venereol* 2015; 29: 566-73 (IF: 2.826, Rang SIGAPS B). (*Contributeur équivalent)
 41. Taieb A, Boralevi F, Seneschal J, Merhand S, Georgescu V, Taieb C, **Ezzedine K**. The atopic dermatitis burden scale—adult: development and validation of a new assessment tool (ABS-A). *Acta Derm Venereol* 2015; 95: 700-5. (IF: 3.025, Rang SIGAPS A).
 42. **Ezzedine K**, Eleftheriadou V, Whitton M, Nan Geel N. Vitiligo. *Lancet* 2015; 386: 74-84. (IF: 45.217, Rang SIGAPS A).
 43. Hosseini M, **Ezzedine K**, Taieb A, Rezvani H. Nucleotide excision repair diseases: Oxidative and energy metabolism as a potential explanation underlying clinical heterogeneity. *J Invest Dermatol* 2015; 135: 341-51 (IF: 7.216, Rang SIGAPS A).
 44. Hu HH, Benfodda M, Dumaz N, Gazal S, Descamps V, Bourillon A, Basset-Seguín N, Riffault A, **Ezzedine K**, Bagot M, Bensussan A, Saiag P, Grandchamp B, Soufir N. A large French case-control study emphasizes the role of rare MC1R variants in melanoma risk. *Biomed Res Int* 2014; 2014:925716. doi: 10.1155/2014/925716. (IF: 1.579, Rang SIGAPS C).
 45. Dreyfus I, Chouquet C, **Ezzedine K**, Henner S, Chiavérini C, Maza A, Pascal S, Rodriguez L, Vabres P, Martin L, Mallet S, Barbarot S, Dupuis J, Mazereeuw-Hautier J. Prevalence of inherited ichthyosis in France: a study using capture-recapture method. *Orphanet J Rare Dis* 2014; 9: 1 (IF: 3.358, Rang SIGAPS B).
 46. Boralevi F, Diallo A, Miquel J, Guerin-Moreau M, Bessis D, Chiavérini C, Plantin P, Hubiche T, Maruani A, Lassalle M, Boursault L, **Ezzedine K**. Clinical phenotype of scabies according to age. *Pediatrics* 2014; 133: e910-6 (IF: 5.473, Rang SIGAPS A).
 47. Eytan O, Morice-Picard F, Sarig O, **Ezzedine K**, Isakov O, Li Q, Ishida-Yamamoto A, Shomron N, Goldsmith T, Fuchs-Telem D, Adir N, Uitto J, Orlov SJ, Taieb A, Sprecher E. Cole Disease Results from Mutations in ENPP1. *Am J Hum Genet* 2013; 93: 752-7 (IF: 10.931, Rang SIGAPS A).
 48. **Ezzedine K**, le Thuaut A, Jouary T, Ballanger F, Taieb A, Bastuji-Garin S. Latent Class Analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes. *Pigment Cell Melanoma res* 2014; 27: 134-9 (IF: 4.619, Rang SIGAPS B).
 49. Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, Picardo M, Taieb A, Cario-André M, **Ezzedine K** *. NLRP1 inflammasome activation and vitiligo/nonsgmental vitiligo progression. *Br J Dermatol* 2014; 170: 816-23 (IF: 4.275, Rang SIGAPS A). (*Contributeur équivalent)
 50. Latreille J, Kesse-Guyot E, Malvy D, Andreeva V, Galan P, Tschachler E, Hercberg S, Guinot C, **Ezzedine K**. Association between dietary intake of n-3 polyunsaturated fatty acids and severity of skin photoaging in a middle-aged Caucasian population. *J Dermatol Sci* 2013; 72: 233-9 (IF: 3.419, Rang SIGAPS B).

51. Ahogo C, **Ezzedine K**, Prey S, Colona V, Diallo A, Boralevi F, Taieb A, Labrèze C. Factors associated with the relapse of infantile hemangiomas in children treated with oral propranolol. *Br J Dermatol* 2013; 169: 1252-6 (IF: 4.275, Rang SIGAPS A).
52. Hadj-Rabia S, Oriot D, Soufir N, Dufresne H, Bourrat E, Mallet S, Poulhalon N, **Ezzedine K**, Grandchamp B, Taieb A, Catteau B, Sarasin A, Bodemer C. Unexpected extradermatological findings in 31 patients with xeroderma pigmentosum type C. *Br J Dermatol* 2013; 168: 1109-13 (IF: 4.275, Rang SIGAPS A).
53. Jdid R, **Ezzedine K**, Latreille J, Galan P, Hercberg S, Malvy D, Tschachler E, Guinot C. MC1R major variants are a risk factor of sleep lines in Caucasian women. *J Eur Acad Dermatol Venereol* 2014; 28: 805-9. (IF: 2.826, Rang SIGAPS B).
54. Morice-Picard F, **Ezzedine K**, Delrue MA, Lacombe D, Taieb A, Boralevi F. Cutaneous manifestations in Costello and Cardiofaciocutaneous syndrome: report of 18 cases and literature review. *Pediatric Dermatol* 2013; 30: 665-73 (IF: 1.015, Rang SIGAPS D).
55. Diallo A, Boniface K, Jouary T, Seneschal J, Morice-Picard F, Prey S, Cario-André M, Mazereeuw-Hautier J, Taieb A, **Ezzedine K**. Development and validation of the K-VSCOR for scoring Koebner's phenomenon in Vitiligo/non-segmental vitiligo. *Pigment Cell Melanoma res* 2013; 26: 402-7 (IF: 4.619, Rang SIGAPS B).
56. Benzekri L, **Ezzedine K**, Gauthier Y. Vitiligo potential repigmentation index (PRI): A simple clinical score that might predict vitiligo lesions ability to repigment under therapy. *Br J Dermatol* 2013; 168: 1143-6 (IF: 4.275, Rang SIGAPS A).
57. Gey A, Diallo A, Seneschal J, Léauté-Labrèze C, Boralevi F, Jouary T, Taieb A, **Ezzedine K**. Auto-immune thyroid stigma in vitiligo: multivariate analysis indicates intricated pathomechanisms. *Br J Dermatol* 2013; 168: 756-61 (IF: 4.275, Rang SIGAPS A).
58. Léauté-Labrèze C, Dumas de la Roque E, Nacka F, Abouelfath A, Grenier N, Rebola M, **Ezzedine K**, Moore N. Double blind randomized trial evaluating the safety and efficacy of oral propranolol in the early phase treatment of infantile haemangioma. *Br J Dermatol* 2013; 169: 181-3 (IF: 4.275, Rang SIGAPS A).
59. Mazereeuw-Hautier J, Dreyfus I, Barbarot S, Maza A, Galera I, Bourrat E, Chiaverini C, **Ezzedine K**, Le Rhun A, Taieb C. IQoL: a new ichthyosis-specific measure of quality of life. *J Am Acad Dermatol* 2013; 69: 82-7 (IF: 4.449, Rang SIGAPS A).
60. Le Clerc S, Taing L, **Ezzedine K**, Latreille J, Labib T, Coulonges C, Bernard A, Melak S, Carpentier W, Malvy D, Jdid R, Galan P, Hercberg S, Morizot F, Guinot C, Tschachler E, Zagury JF. A Genome-Wide Association Study in Caucasian women points out for a role of the STXBP5L gene in facial photoageing. *J Invest Dermatol* 2013; 133: 929-35 (IF: 7.216, Rang SIGAPS A).
61. Prey S, **Ezzedine K**, Mazereeuw-Hautier J, Eschard C, Barbarot S, Boralevi F, Taieb A, Léauté-Labrèze C, and on behalf of the Groupe de Recherche Clinique en Dermatologie Pédiatrique. IFAG and childhood rosacea: a possible link? *Pediatric Dermatol* 2013; 30: 429-32 (IF: 1.015, Rang SIGAPS D).
62. Prey S, **Ezzedine K**, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski, Kostrezwa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chêne G, Taieb A. Imatinib mesylate in systemic sclerosis associated- diffuse skin fibrosis: a phase II randomized controlled double-blinded versus placebo multicentric trial. *Br J Dermatol* 2012; 167: 1138-44 (IF: 4.275, Rang SIGAPS A).
63. **Ezzedine K**, Mauger E, Latreille E, Jdid R, Malvy D, Gruber F, Galan P, Hercberg S, Tschachler E, Guinot C. Freckles and solar lentigines have different risk factors in Caucasian women. *J Eur Acad Dermatol Venereol* 2013; 27: e345-e356 (IF: 2.826, Rang SIGAPS B).
64. Latreille J, Kesse-Guyot E, Malvy D, Andreeva V, Galan P, Tschachler E, Hercberg S, Guinot C, **Ezzedine K**. Dietary monounsaturated fatty acids intake and risk of skin photoaging. *Plos One* 2012; 7: e44490 (IF: 3.234, Rang SIGAPS B).
65. Seneschal J, Kubica E, Boursault L, Stokkermans J, Labrèze C, Milpied B, **Ezzedine K**, Taieb A. Exogenous inflammatory acne due to combined application of cosmetic and facial rubbing. *Dermatology* 2012; 224: 221-3 (IF: 1.569, Rang SIGAPS C).
66. Droitcourt C, Milpied B, **Ezzedine K**, Hubiche T, Belin E, Akpadjan F, Taieb A, Seneschal J. Interest of high dose pulse corticosteroid therapy combined with methotrexate for severe alopecia areata: a retrospective case series. *Dermatology* 2012; 224: 369-73 (IF: 1.569, Rang SIGAPS C).
67. **Ezzedine K**, Droitcourt C, Ged C, Diallo A, Hubiche T, de Verneuil H, Boralevi F, Taieb A. Usefulness of a global clinical ichthyosis vulgaris scoring system for predicting common FLG null mutations in an adult Caucasian population. *Br J Dermatol* 2012; 167: 1165-9 (IF: 4.275, Rang SIGAPS A).
68. **Ezzedine K**, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, Goh BK, Anbar T, Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri1 L, Spritz R, Y Gauthier Y, Hann SK, Picardo M, A Taieb. On behalf of the Vitiligo Global Issue Consensus Conference panelists*. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. *Pigment Cell Melanoma res* 2012; 25: E1-13 (IF: 4.619, Rang SIGAPS B).
69. AlGhamdi KM, Khurram H, Taieb A, **Ezzedine K**. Treatment of generalized vitiligo with anti TNF- α agents. *J Drugs Dermatol* 2012; 11: 534-9 (IF: 1.446, Rang SIGAPS D).
70. **Ezzedine K**, Diallo A, Léauté-Labrèze C, Seneschal J, Boniface K, Cario-André M, Prey S,

- Ballanger F, Boralevi F, Jouary T, Mossalayi D, Taieb A. Pre vs post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo. *Br J Dermatol* 2012; 167: 490-5 (IF: 4.275, Rang SIGAPS A).
- 71.** Ezzedine K, Diallo A, Léauté-Labrèze C, Séneschal J, Prey S, Ballanger F, Alghamdi K, Cario-André M, Jouary T, Gauthier Y, Taieb A. Halo nevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo. *Br J Dermatol* 2012; 166: 539-44 (IF: 4.275, Rang SIGAPS A).
- 72.** Ricard AS, Pain C, Daubos A, Ezzedine K, Lamrissi-Garcia I, Bibeyran A, Guyonnet-Duperat V, Taieb A, Cario-André M. Study of CCN3 (Nov) and DDR1 in normal melanocytes and vitiligo skin. *Exp dermatol* 2012; 21: 411-6 (IF: 3.762, Rang SIGAPS A).
- 73.** AlGhamdi KM, Kumar A, Taieb A, Ezzedine K. Assessment Methods for the Evaluation of Vitiligo. *J Eur Acad Dermatol Venereol* 2012; 26: 1463-71 (IF: 2.826, Rang SIGAPS B).
- 74.** Jin Y, Birlea SA, Fain PR, Ferrara TM, Ben S, Riccardi SL, Cole JB, Gowan K, Holland PJ, Bennett DC, Luiten RM, Wolkerstorfer A, van der Veen JPW, Hartmann A, Eichner S, Schuler G, van Geel N, Lambert J, Kemp EH, Gawkrödger DJ, Weetman AP, Taieb A, Jouary T, Ezzedine K, Wallace MR, McCormack WT, Picardo M, Leone G, Overbeck A, Silverberg NB, Spritz RA. Genome-wide association study identifies melanocyte-specific and immunoregulatory susceptibility loci for generalized vitiligo. *Nat genet* 2012; 44: 676-80 (IF: 29.352, Rang SIGAPS A).
- 75.** Mazereeuw-Hautier J, Dreyfus I, Barbarot S, Serrentino L, Bourdon-Lannoy E, Ezzedine K, Maza A, Aujoulat I, Le Rhun A. Factors influencing quality of life of inherited adult ichthyosis: a qualitative study using focus groups. *Br J Dermatol* 2012; 166: 646-8 (IF: 4.275, Rang SIGAPS A).
- 76.** Ezzedine K, Diallo A, Léauté-Labrèze C, Séneschal J, Mossalayi D, AlGhamdi K, Prey S, Bouchtnei S, Cario-André M, Boralevi F, Jouary T, Taieb A. Halo nevi association in nonsegmental vitiligo influences age of onset and depigmentation pattern. *Arch Dermatol* 2012; 148: 497-502 (IF: 4.789, Rang SIGAPS A).
- 77.** Hu H-H, Guedj M, Descamps V, Jouary T, Bourillon A, Ezzedine K, Taieb A, Bagot M, Bensussan A, Saiag P, Grandchamp B, Basset-Seguín N, Soufir N. Assessment of Tyrosinase variants and skin cancer risk in a large cohort of French subjects. *J Dermatol Sci* 2011; 63: 127-33 (IF: 3.419, Rang SIGAPS B).
- 78.** van Geel N, Reinhart S, Taieb A, Picardo M, Böhm M, Gawkrödger DJ, Schallreuter K, Bennett DC, van der Veen W, Moretti S, Westerhof W, Ezzedine K, Gauthier Y, and on behalf of the other VETF members. Koebner phenomenon in vitiligo: European position paper. *Pigment Cell Melanoma Res* 2011; 24: 564-73 (IF: 4.619, Rang SIGAPS B).
- 79.** Ezzedine K, Diallo A, Léauté-Labrèze C, Mossalayi D, Gauthier Y, Bouchtnei S, Cario-André M, Seneschal J, Boralevi F, Jouary T, Taieb A. Multivariate analysis of factors associated with early onset segmental and non-segmental vitiligo: a prospective observational study of 213 patients. *Br J Dermatol* 2011; 165: 44-9 (IF: 4.275, Rang SIGAPS A).
- 80.** Elfakir A, Ezzedine K, Latreille J, Ambroisine L, Jdid R, Galan P, Hercberg S, Gruber F, Malvy D, Tschachler E, Guinot C. Polymorphismes du MC1R et photovieillissement du visage. *Ann Dermatol Venereol* 2011; 138 : 385-9 (IF: 0.919, Rang SIGAPS E).
- 81.** Droitcourt C, Touboul D, Ged C, Ezzedine K, Cario-André M, de Verneuil H, Colin J, Taieb A. A prospective study of filaggrin null mutations in Keratoconus patients with or without atopic disorders. *Dermatology* 2011; 222:336-341 (IF: 1.569, Rang SIGAPS C).
- 82.** Belin E, Ezzedine K, Lalanne N, Beylot-Barry M, Stanislas S, Taieb A, Vergier B, Jouary T. Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. *Br J Dermatol* 2011; 165: 985-9 (IF: 4.275, Rang SIGAPS A).
- 83.** Ezzedine K, Gauthier Y, Léauté-Labrèze C, Marquez S, Bouchtnei S, Jouary T, Taieb A. Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. *J Am Acad Dermatol* 2011; 65: 965-71 (IF: 4.449, Rang SIGAPS A).
- 84.** Birlea SA, Jin Y, Bennet DC, Herbstman DM, Wallace MR, McCormack WT, Kemp EH, Gawkrödger DJ, Weetman AP, Picardo M, Leone G, Taieb A, Jouary T, Ezzedine K, van Geel N, Lambert J, Overbeck A, Fain PR, Spritz RA. Comprehensive analysis of vitiligo candidate genes supports primary association of XBP1, and FOXP3, and TSLP. *J Invest Dermatol* 2011; 131: 271-381 (IF: 7.216, Rang SIGAPS A).
- 85.** Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, Bennett DC, Wallace MR, McCormack WT, Kemp EH, Gawkrödger DJ, Weetman AP, Picardo M, Leone G, Taieb A, Jouary T, Ezzedine K, Van Geel N, Lambert J, Overbeck A, Spritz RA. Genome-Wide Analysis Identifies a Quantitative Trait Locus in the MHC Class II Region Associated with Generalized Vitiligo Age of Onset. *J Invest Dermatol* 2011; 131: 1308-12 (IF: 7.216, Rang SIGAPS A).
- 86.** Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, Mailloux CM, Sufit AJD, Hutton SM, Amadi-Myers A, Bennett DC, Wallace MR, McCormack WT, Kemp EH, Gawkrödger DJ, Weetman AP, Picardo M, Leone G, Taieb A, Jouary T, Ezzedine K, Geel N, Lambert J, Overbeck A, Spritz RA. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. *N Engl J Med* 2010; 362: 1686-97 (IF: 55.873, Rang SIGAPS A).
- 87.** Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, Mailloux CM, Sufit AJD, Hutton SM, Amadi-Myers A, Bennett DC, Wallace MR, McCormack WT, Kemp EH,

- Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taïeb A, Jouary T, **Ezzedine K**, Geel N, Lambert J, Overbeck A, Spritz RA. Common variants of FOXP1 are associated with generalized vitiligo. *Nat Genet* 2010; 42: 576-8 (IF: 29.352, Rang SIGAPS A).
- 88.** **Ezzedine K**, Latreille J, Kesse-Guyot E, Galan P, Hercberg S, Guinot C, Malvy D. Incidence of skin cancers during five-year follow-up after stopping antioxidant vitamins and mineral supplementation. *Eur J Cancer* 2010; 46: 3316-22 (IF: 5.417, Rang SIGAPS B).
- 89.** Sissoko D, **Ezzedine K**, Giry C, Moendandzé A, Lemout T, D'Ortenzio E, Pettinelli F, Malvy D. Seroepidemiology of Dengue virus in Mayotte, Indian Ocean, 2006. *PLoS One* 2010; 5: e14141 (IF: 3.234, Rang SIGAPS B).
- 90.** Larrieu S, Poudroux N, Pistone T, Receveur MC, Sissoko D, Filleul L, **Ezzedine K**, Malvy D. Factors associated with persistence of arthralgia among chikungunya virus-infected travellers: report of 42 French cases. *J Clin Virol* 2010; 41: 85-8 (IF: 3.016, Rang SIGAPS A).
- 91.** **Ezzedine K**, Pistone T, Gaudin AF, Hercberg S, Nachbaur G, Malvy D. Malaria prevention behaviour and risk awareness in French adult travelers. *Travel Med Infect Dis* 2010; 8: 13-21 (IF: 1.538, Rang SIGAPS C).
- 92.** Vanhecke C, Malvy D, Guevart E, Lalogue V, **Ezzedine K**. Paederus dermatitis : à propos de 74 cas groupés au Centre Médical Français de Conakry, Guinée, Octobre- Décembre 2008. *Ann Dermatol Venereol* 2010; 137: 189-93 (IF: 0.919, Rang SIGAPS E).
- 93.** Sissoko D, **Ezzedine K**, Moendandzé A, Giry C, Renault P, Malvy D. Field evaluation of clinical features during chikungunya outbreak in Mayotte, 2005-2006: implications for community-based active surveillance purposes. *Trop Med Int Health* 2010; 15: 600-7 (IF: 2.329, Rang SIGAPS B).
- 94.** Elfakir A, **Ezzedine K**, Latreille J, Ambroisine L, Jdid R, Galan P, Hercberg S, Gruber F, Malvy D, Tschachler E, Guinot C. Functional MC1R gene variants are associated with an increased risk of severe photoaging of facial skin. *J Invest Dermatol* 2010; 130: 1107-15 (IF: 7.216, Rang SIGAPS A).
- 95.** Jouary T, Legros C, Lallane N, Versapuech J, **Ezzedine K**, Vergier B, Delaunay M, Velly JF, Taieb A. Neoadjuvant chemotherapy: a new selection criterion for candidate surgery of low tumor burden metastases from malignant melanoma. *Br J Dermatol* 2010; 163: 183-7 (IF: 4.275, Rang SIGAPS A).
- 96.** Vanhecke C, Guevart E, **Ezzedine K**, Receveur MC, Jamonneau V, Bucheton B, Camara M, Vincendeau P, Malvy D. La trypanosomose humaine africaine en faciès épidémiologique de mangrove. Présentation, déterminants et prise en charge dans le contexte de la Guinée (2005-2007). *Pathol Biol* 2010; 58: 210-6 (IF: 1.200, Rang SIGAPS E).
- 97.** Robin S, Ramful D, Zettor J, Benhamou L, Jaffar-Bandjee MC, Rivière JP, Marichy J, **Ezzedine K**, Alessandri L. Severe bullous skin lesions associated with chikungunya virus infection in small infants. *Eur J Pediatr* 2010; 169: 67-72 (IF: 1.890, Rang SIGAPS C).
- 98.** Vereecken P, Awada A, Suciú S, Castro G, Morandini R, Litynska A, Lienard D, **Ezzedine K**, Ghanem G, Heenen M. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. *Melanoma Res* 2009; 19: 316-20 (IF: 2.282, Rang SIGAPS C).
- 99.** Sans V, Dumas de la Roque E, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, Lipsker D, Dupuis E, **Ezzedine K**, Vergnes P, Taïeb A, Léauté-Labrèze C. Propanolol for severe infantile hemangiomas : a follow-up report. *Pediatrics* 2009; 124: e423-e431 (IF: 5.473, Rang SIGAPS A).
- 100.** Kostopoulou P, Jouary T, Quintard B, **Ezzedine K**, Marques S, Boutchnei S, Taieb A. Objective vs subjective factors in the psychological impact of vitiligo : the experience of a French referral centre. *Br J Dermatol* 2009; 161: 128-33 (IF: 4.275, Rang SIGAPS A).
- 101.** Latreille J, **Ezzedine K**, Elfakir A, Ambroisine L, Gardinier S, Galan P, Hercberg S, Gruber F, Rees J, Tschachler E, Guinot C. MC1R gene polymorphism affects skin color measured by reflectance in a population of French adult women. *Photochem Photobiol* 2009; 85: 1451-8 (IF: 2.266, Rang SIGAPS D).
- 102.** Sissoko D, Malvy D, **Ezzedine K**, Renault P, Moscetti F, Ledrans M, Pierre V. Post-epidemic chikungunya disease in Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. *PLoS Negl Trop Dis* 2009; 3: e389 (IF: 4.446, Rang SIGAPS A).
- 103.** Valet F, **Ezzedine K**, Malvy D, Mary JY, Guinot C. Reliability assessment of four severity scales depicting skin aging features. *Br J Dermatol* 2009; 161: 153-8 (IF: 4.275, Rang SIGAPS A).
- 104.** Rambert J, Mamani-Matsuda M, Moynet D, Bubus P, Delplat V, Kauss T, Dehais J, Schaevebeke T, **Ezzedine K**, Malvy D, Vincendeau P, Mossalayi D. Molecular blocking of CD23 supports its role in the pathogenesis of arthritis. *PLoS One* 2009; 4: e4834 (IF: 3.234, Rang SIGAPS B).
- 105.** **Ezzedine K**, Pistone T, Boisvert M, Receveur MC, Schuffenecker I, Zeller H, Lafon ME, Fleury H, Malvy D. Cluster of chikungunya virus infection in travellers returning from Senegal, 2006. *J Travel Med* 2009; 4: 289-91 (IF: 1.579, Rang SIGAPS C).
- 106.** Sissoko D, Moendandze A, Malvy D, Giry C, **Ezzedine K**, Solet J-L, Pierre V. Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005-2006: a population-based survey. *PLoS One* 2008; 3: e3066 (IF: 3.234, Rang SIGAPS B).

- 107.** de Carsalade GY, Receveur MC, **Ezzedine K**, Saget J, Achirafi A, Bobin P, Malvy D. Dépistage actif intra-domiciliaire différé de la lèpre: expérience de l'équipe de dépistage sur l'île de Mayotte. *Bull Soc Path Exot* 2008; 100: 32-5.
- 108.** **Ezzedine K**, Amiel A, Vereecken P, Simonart T, Schietse B, Seymons K, Ndiaye BS, Van de Leemput C, Lambert J, Heenen M. BlackSkin Dermatology Online, from the project to the website: a needed collaboration between North and South. *J Eur Acad Dermatol Venereol* 2008; 22: 1193-9 (IF: 2.826, Rang SIGAPS B).
- 109.** Pistone T, Schwarzingler M, Chauvin P, **Ezzedine K**, Receveur MC, Djossou F, Siriwardana M, Larouzé B, Malvy D. Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: cost-effectiveness analysis from the perspective of the French Healthcare System. *Health Policy* 2008; 88: 186-99 (IF: 1.907, Rang SIGAPS C).
- 110.** **Ezzedine K**, Malvy D, Receveur MC, Pistone T, Crevon L, Lemardeley P, Josse R. Cluster of eosinophilic meningitis attributable to *A. cantonensis* infection in French policemen troop returning from the Pacific Islands. *Travel Med Infect Dis* 2008; 6: 301-4 (IF: 1.538, Rang SIGAPS C).
- 111.** **Ezzedine K**, Malvy D, Mauger E, Galan P, Hercberg S, Guinot C. Artificial and natural ultraviolet radiation exposure: beliefs and behaviour of 7,200 French adults. *J Eur Acad Dermatol Venereol* 2008; 22: 186-94 (IF: 2.826, Rang SIGAPS B).
- 112.** Valet F, Mary JY, **Ezzedine K**, Guinot C. Quality assessment of ordinal scale reproducibility: log-linear models provided useful information on scale structure. *J Clin Epidemiol* 2008; 61: 983-90 (IF: 3.417, Rang SIGAPS A).
- 113.** Bley D, Vernazza-Licht N, Pistone T, Reviriego J, Djossou F, Receveur MC, **Ezzedine K**, Malvy D. Understanding and awareness of malaria among 103 French individuals traveling to endemic areas, having consulted the Bordeaux university hospital travel clinic, France. *Med Mal Infect* 2007; 37: 678-83 (IF: 1.237, Rang SIGAPS E).
- 114.** Hercberg S, **Ezzedine K**, Guinot C, Preziosi P, Galan P, Bertrais S, Estaquio C, Briançon S, Favier A, Malvy D. Antioxidant supplementation increases the risk of skin cancers in women but not in men. *J Nutr* 2007; 137: 2098-105 (IF: 3.875, Rang SIGAPS B).
- 115.** Ambroisine L, **Ezzedine K**, Elfakir A, Gardinier S, Latreille J, Mauger E, Tenenhaus M, Guinot C. Relationships between visual and tactile features and skin biophysical parameters in human facial skin. *Skin Res Technol* 2007; 13: 176-83 (IF: 1.536, Rang SIGAPS D).
- 116.** **Ezzedine K**, Guinot C, Mauger E, Pistone T, Rafii N, Receveur MC, Galan P, Hercberg S, Malvy D. Expatriates in high UV index and tropical countries: sun-exposure and protection behaviour in 9416 French adults. *J Travel Med* 2007; 14: 85-91 (IF: 1.579, Rang SIGAPS C).
- 117.** **Ezzedine K**, Guinot C, Mauger E, Pistone T, Receveur MC, Galan P, Hercberg S, Malvy D. Travellers to high UV index countries: sun-exposure behaviour in 7822 French adults. *Travel Med Infect Dis* 2007; 5: 176-82 (IF: 1.538, Rang SIGAPS C).
- 118.** Pistone T, Guibert P, Gay F, Malvy D, **Ezzedine K**, Receveur MC, Siriwardana M, Larouzé B, Bouchaud O. Malaria risk perception, knowledge and prophylaxis practices among travellers of African ethnicity living in Paris and visiting their country of origin in sub-Saharan Africa. *Trans R Soc Trop Med Hyg* 2007; 101: 990-5 (IF: 1.839, Rang SIGAPS B).
- 119.** Malvy D, **Ezzedine K**, Lançon F, Halioua B, Rezvani A, Bertrais S, Chanzy B, Daniloski M, Malkin JE, Morand P, De Labareyre C, Hercberg S, El Hasnaoui A. Epidemiology of orofacial herpes simplex virus infections in a general population in France: results of the Herpimax study. *J Eur Acad Dermatol Venereol* 2007; 21: 1398-403 (IF: 2.826, Rang SIGAPS B).
- 120.** **Ezzedine K**, Darie H, Le Bras M, Malvy D. Skin features accompanying imported human African trypanosomiasis: hemolympathic *Trypanosoma gambiense* infection among two French expatriates with dermatologic manifestations. *J Travel Med* 2007; 14: 192-6 (IF: 1.579, Rang SIGAPS C).
- 121.** Guinot C, Malvy D, Mauger E, **Ezzedine K**, Latreille J, Tenenhaus M, Galan P, Hercberg S, Tschachler E. Self-reported skin sensitivity in a general adult population in France: data of the SU.VI.MAX cohort. *J Eur Acad Dermatol Venereol* 2006; 20: 380-90 (IF: 2.826, Rang SIGAPS D).
- 122.** Guinot C, **Ezzedine K**, Mauger E, Ambroisine L, Latreille J, Preziosi P, Galan P, Chapuy MC, Arnaud S, Meunier JP, Tschachler E, Hercberg S, Malvy D. Phototype, vitamin D status and bone mineral density in women at risk for osteoporosis. *Rev Med Int* 2006; 27: 369-74 (IF: 1.074, Rang SIGAPS B).
- 123.** Malvy D, Halioua B, Lançon F, Rezvani A, Bertrais S, Chanzy B, Daniloski M, **Ezzedine K**, Malkin JE, Morand P, De Labareyre C, Hercberg S, El Hasnaoui A. Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the herpimax study. *Sex Transm Dis* 2005; 32: 499-505 (IF: 2.842, Rang SIGAPS C).
- 124.** Guinot C, Malvy D, Latreille J, **Ezzedine K**, Latreille J, Galan P, Tenenhaus M, Ambroisine L, Lê S, Hercberg S, Tschachler E. Sun reactive skin type in a French general adult population. *Photochem Photobiol* 2005; 81: 934-40 (IF: 2.266, Rang SIGAPS D).

1. Amazan E, **Ezzedine K**, Mossalayi D, Taieb A, Boniface K, Seneschal J. Expression of interleukin-1 alpha in amicrobial pustulosis of the skin folds with complete response to Anakinra. *J Am Acad Dermatol* 2014; 71: e53-6.4 (IF: 4.449, Rang SIGAPS A).
2. Dousset L, Seneschal J, Boniface K, Charreau S, **Ezzedine K**, Milpied B, Mossalayi MD, McGrath JA, Lecron JC, Taieb A. A Th2 Cytokine Interleukin 31 Signature in a Case of Sporadic Lichen Amyloidosis. *Acta Derm Venereol* 2015; 95: 223-4 (IF: 3.025, Rang SIGAPS A).
3. Seneschal J, Guillet S, **Ezzedine K**, Taieb A, Milpied B. Alternative procedure to allow continuation of Dapsone therapy despite serious adverse reaction in a case of Dapsone Sensitive Erythema Elevatum Diutinum. *Dermatology* 2012; 224: 115-9 (IF: 1.569, Rang SIGAPS C).
4. Cante V, Pham-Ledard A, Imbert E, **Ezzedine K**, Léauté-Labrèze C. First report of topical timolol treatment in primarily ulcerated perineal hemangioma. *Arch Dis Child Fetal Neonatal Ed* 2012; 97: F155-6 (IF: 3.120, Rang SIGAPS A).
5. **Ezzedine K**, Amazan E, Seneschal J, Cario-André M, Léauté-Labrèze C, Vergier B, Boralevi F, Taieb A. Follicular vitiligo: a new form of vitiligo. *Pigment Cell Melanoma Res* 2012; 25: 527-9 (IF: 4.619, Rang SIGAPS B).
6. Receveur M, **Ezzedine K**, Pistone T, Malvy D. Chikungunya infection in a French traveller returning from the Maldives, October, 2009. *Euro Surveill* 2010; 15: 19494 (IF: 5.722, Rang SIGAPS A).
7. Pradines B, Pistone T, **Ezzedine K**, Briolant S, Bertaux L, Receveur MC, Parzy D, Millet P, Rogier C, Malvy D. Quinine-resistant malaria in traveler returning Senegal, 2007. *Emerg Infect Dis* 2010; 16: 546-8 (IF: 6.751, Rang SIGAPS A).
8. Houdon L, Flodrops H, Rocaboy M, Bintner M, Fériot JP, Tournebize P, Renouil M, **Ezzedine K**, Malvy D. Two patients with acute imported neuroschistosomiasis due to *Schistosoma mansoni*. *J Travel Med* 2010; 17: 274-7 (IF: 1.579, Rang SIGAPS C).
9. Pham-Ledard A, **Ezzedine K**, Couprie B, Begueret H, Boralevi F, Taieb A. Papillomatose confluente et réticulée de Gougerot et Carteaud faciale ou "hyperkeratotic head and neck Malassezia dermatosis". *Ann Dermatol Venereol* 2010; 137: 451-4 (IF: 0.919, Rang SIGAPS E).
10. **Ezzedine K**, Malvy D, Beylot C, Longy-Boursier M. Autochthonous leprosy in metropolitan France presenting with a diffuse infiltration of the face and febrile illness. *Int J Dermatol* 2009; 48: 69-72 (IF: 1.312, Rang SIGAPS D).
11. **Ezzedine K**, Malvy D, Mamani-Matsuda M, Autran B, Tolou H, Receveur MC, Pistone T, D, Mossalayi D. Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. *BMC Infect Dis* 2009; 9: 200 (IF: 2.613, Rang SIGAPS C).
12. Pistone T, **Ezzedine K**, Accocebery I, Receveur MC, Juguet F, Malvy D. Ectopic cutaneous schistosomiasis – Perigenital infiltrative granulomata in a 34-year-old pregnant woman. *Travel Med Infect Dis* 2008; 6: 155-7 (IF: 1.538, Rang SIGAPS C).
13. **Ezzedine K**, Cazanave C, Pistone T, Receveur MC, Neau D, Ragnaud JM, Malvy D. Dual infection by chikungunya virus and other imported infectious agent in a traveller returning from India. *Travel Med Infect Dis* 2008; 6: 152-4 (IF: 1.538, Rang SIGAPS C).
14. **Ezzedine K**, Simonart T, Candaele M, Malvy D, Heenen M. Concomitant Xeroderma pigmentosum and disseminated small plaque psoriasis: first case of an antinomic association. *Cases J* 2008; 1: 74.
15. **Ezzedine K**, Pistone T, Schuffenecker I, Receveur M-C, Malvy D. An imported case of chikungunya fever from Madagascar: use of the sentinel traveller for detecting emerging arboviral infections in tropical and European countries. *Travel Med Infect Dis* 2008; 7: 52-4 (IF: 1.538, Rang SIGAPS C).
16. **Ezzedine K**, Malvy D, Steels E, De Dobbeleer G, Struelens M, Jacobs F, Heenen M. Imported melioidosis with an isolated cutaneous presentation in a 90-year-old traveller. *Bull Soc Path Exot* 2007; 100: 22-5.
17. **Ezzedine K**, Accocebery I, Malvy D. Oral histoplasmosis following radiation therapy for laryngeal squamous cell carcinoma. *J Am Acad Dermatol* 2007; 56: 871-3 (IF: 4.449, Rang SIGAPS A).
18. **Ezzedine K**, Cressend T, Pistone T, Receveur MC, Diéval C, Malvy D. Haemoglobinuria in a 38-year-old French expatriate man living in Cameroon following artemisinin-based antimalarial treatment. *Travel Med Infect Dis* 2007; 5: 256-8 (IF: 1.538, Rang SIGAPS C).
19. **Ezzedine K**, Malvy D, Dhaussy I, Steels E, De Dobbeleer G, Heenen M. Onchocerciasis-associated limb swelling in a traveller returning from Cameroon. *J Travel Med* 2006; 13: 50-3 (IF: 1.579, Rang SIGAPS C).
20. Malvy D, **Ezzedine K**, Pistone T, Receveur MC, Longy-Boursier M. Extensive cutaneous larva migrans with folliculitis mimicking pseudometameric herpes zoster presentation in a traveller returning from Thailand. *J Travel Med* 2006; 13: 244-7 (IF: 1.579, Rang SIGAPS C).
21. Malvy D, **Ezzedine K**, Receveur MC, Pistone T, Mercié P, Longy-Boursier M. Extra-pulmonary paragonimiasis with unusual arthritis and cutaneous features among a tourist returning from Gabon. *Travel Med Infect Dis* 2006; 6: 340-2 (IF: 1.538, Rang SIGAPS C).
22. Duvignaud A, Receveur MC, **Ezzedine K**, Pistone T, Malvy D. Visceral leishmaniasis due to *Leishmania infantum* in a kidney transplant recipient living in France. *Travel Med Infect Dis* 2015; 13: 115-6 (IF: 1.538, Rang SIGAPS C).

23. Jouary T, Guillet S, Droitcourt C, Dutriaux C, **Ezzedine K**, Goussot JF, Taieb A. Lichen sclerosus mimicking halo-nevus comedonicus. *J Eur Acad Dermatol Venereol* 2015 (in press) (IF: 2.826, Rang SIGAPS B).
24. Malvy D, Khatibih S, Rivière B, Prudhomme L, **Ezzedine K**. Challenging issues and pitfalls for diagnosis of Human African trypanosomiasis in a Gabonese visitor, France. *Travel Med Infect Dis* 2014; 12: 778-80 (IF: 1.538, Rang SIGAPS C).
25. Mahé A, **Ezzedine K**. Letter to the Editor concerning the article "Geographical ancestry is a key determinant of epidermal morphology and dermal composition". *Br J Dermatol* 2014; 171: 1598-9 (IF: 4.275, Rang SIGAPS A).
26. Gey A, Milpied B, Dutriaux C, Mateus C, Robert C, Perro G, Taieb A, **Ezzedine K**, Jouary T. Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? *J Eur Acad Dermatol Venereol* 2014 (in press) (IF: 2.826, Rang SIGAPS B).
27. Bertolotti A, Conte H, Louis F, Dutriaux C, **Ezzedine K**, Mélard P, Vergier B, Taieb A, Jouary T. Merkel Cell Carcinoma: Complete Clinical Remission Associated With Disease Progression Metastatic Melanoma with Leukaemia-like Evolution. *JAMA Dermatol* 2013; 149: 501-502 (IF: 4.426, Rang SIGAPS A).
28. Taieb A, **Ezzedine K**. Vitiligo: the white armor? *Pigment Cell Melanoma res* 2013; 26: 286-7 (IF: 4.619, Rang SIGAPS B).
29. Bertolotti A, Conte H, Amazan E, Dutriaux C, **Ezzedine K**, Parrens M, Vergier B, Taieb A, Jouary T. Metastatic Melanoma with Leukaemia-like Evolution. *Acta Derm Venereol* 2013; 93: 729-30 (IF: 3.025, Rang SIGAPS A).
30. **Ezzedine K**, Pistone T. Multiple pruritic papules of the buttocks. *CMAJ* 2013; 185: E213 (IF: 5.959, Rang SIGAPS A).
31. **Ezzedine K**, Belin E, Guillet S, D'Almeida M, Droitcourt C, Accocebery I, Milpied B, Jouary T, Malvy D, Taieb A. Cutaneous hyphomycosis due to *P. Lilacinus*. *Acta Derm Venereol* 2012; 92: 156-7 (IF: 3.025, Rang SIGAPS A).
32. **Ezzedine K**, Simonart T, Malvy D, Bourgoin C, Noel JC. Cutaneous verrucous carcinoma arising in lupus vulgaris. *J Dermatol* 2012; 39: 505-7 (IF: 2.252, Rang SIGAPS C).
33. **Ezzedine K**, Milpied B, Ohayon-Courtès C, Genillier-Foin N, Peyromat M, Taieb A, Léauté-Labrèze C. Are post-vaccinal persistent itching nodules related to the use of local anaesthetic patches? A hypothesis to confirm. *Contact Dermatitis* 2012; 66: 343-4 (IF: 3.747, Rang SIGAPS B).
34. Prevost P, Bédry R, Lacoste D, **Ezzedine K**, Haramburu F, Milpied B. Hypersensitivity syndrome with olanzapine confirmed by patch tests. *Eur J Dermatol* 2012; 26: 126-7 (IF: 1.990, Rang SIGAPS C).
35. Prey S, Haberstroh G, Vergier B, Taieb A, Wassef M, **Ezzedine K**, Léauté-Labrèze C. Successful treatment of intravascular papillary endothelial hyperplasia (IPEH) by the beta-adrenergic antagonist nevigolol. *Br J Dermatol* 2012; 166: 1147-9 (IF: 4.275, Rang SIGAPS A).
36. Gauzere BA, Malvy D, Filleul L, Ramful D, Jaffar-Bandjee MC, El Bock M, **Ezzedine K**, Vandroux D. Intensive Care Unit Admission for Pandemic (H1N1) 2009, Reunion Island, 2009. *Emerg Infect Dis* 2011; 17: 140-1 (IF: 6.751, Rang SIGAPS A).
37. Conte H, Milpied B, Kaloga M, Lalanne N, Belin E, Jouary T, Taieb A, **Ezzedine K**. Treatment of pre-ulcerative necrobiosis lipoidica with infliximab. *Acta Dermatol Venereol* 2011; 91: 587-8 (IF: 3.025, Rang SIGAPS A).
38. **Ezzedine K**, Solé G, Guillet S, Belin E, Droitcourt C, Jouary T, taieb A. An extraordinary « sunburn » in a black patient. *Br J Dermatol* 2011; 164 : 1398-400 (IF: 4.275, Rang SIGAPS A).
39. Kubica E, **Ezzedine K**, Lalanne N, Dartial Y, Taieb A, Milpied B. Oral alitretinoin in chronic refractory hand eczema: a "real life" case-series of 12 patients. *Eur J Dermatol* 2011 ; 21 : 454-6 (IF: 1.990, Rang SIGAPS C).
40. Imbert E, Milpied B, Jouary T, Versapuech J, Goussot JF, Taieb A, **Ezzedine K**. Penile swelling and ulceration. *Acta Derm Venereol* 2010; 90: 81-2 (IF: 3.025, Rang SIGAPS A).
41. **Ezzedine K**, Hercberg S, Malvy D. Antioxidant supplementation and risk of skin cancer. *Arch Dermatol* 2010; 146: 567-8 (IF: 4.789, Rang SIGAPS A).
42. **Ezzedine K**, Pistone T, Guir V, Malvy D. Painful Buruli ulcer in a Malian visitor to France. *Acta Dermatol Venereol* 2010; 90: 424 (IF: 3.025, Rang SIGAPS A).
43. **Ezzedine K**, Belin E, Pistone T, Milpied B, Jouary T, Taieb A, Longy-Boursier M, Malvy D. Orificial tuberculosis in an immunocompetent careworker. *Acta Dermatol Venereol* 2010; 90: 552-3 (IF: 3.025, Rang SIGAPS A).
44. **Ezzedine K**, Hercberg S, Malvy D. Antioxidant supplements and their risk of skin cancer. *Clin Dermatol* 2010; 28: 695-6 (IF: 2.470, Rang SIGAPS C).
45. **Ezzedine K**, Wissing KM, Jacobs F, Rodriguez H, Malvy D, Simonart T. Recurrent *Scedosporium apiospermum* skin infection in a renal transplant recipient. *J Eur Acad Dermatol Venereol* 2009; 23: 95-6 (IF: 2.826, Rang SIGAPS B).
46. **Ezzedine K**, Simonart T, Vereecken P, Heenen M. Facial actinic lichen planus following the Blaschko's lines: successful treatment with topical 0.1% pimecrolimus cream. *J Eur Acad Dermatol Venereol* 2009; 23: 458-9 (IF: 2.826, Rang SIGAPS B).
47. **Ezzedine K**, Pistone T, Marsollier L, Cottin J, Malvy D. Buruli ulcer in a longterm traveller to Senegal. *Emerg Infect Dis* 2009; 15: 118-9. (IF: 6.751, Rang SIGAPS A).
48. Lalanne N, Ezzedine K, Vergier B, Jouary T. Fatal lymphangiosarcoma revealed by lymphoedema of the goat. *Acta Derm Venereol* 2009; 3: 318-9 (IF: 3.025, Rang SIGAPS A).
49. Conte H, **Ezzedine K**, Jouary T, Hubiche T, Taieb A, Milpied B. Eventration caused by

methotrexate in a psoriatic patient. *J Eur Acad Dermatol Venereol* 2009; 24: 76-7 (IF: 2.826, Rang SIGAPS B).

50. Droitcourt C, Adenis-Lamarre E, **Ezzedine K**, Taieb A, Jouary T. Blaschkolinear melanocytic congenital nevus. *Dermatology* 2009; 182-3 (IF: 1.569, Rang SIGAPS C).
51. **Ezzedine K**, Favier A, Malvy D, Hercberg S. Reply to Schrauzer. *J Nutr* 2008; 821-2 (IF: 3.875, Rang SIGAPS B).
52. **Ezzedine K**, Malvy D, Briançon S, Hercberg S. Reply to Green et al. *J Nutr* 2008; 138: 979 (IF: 3.875, Rang SIGAPS B).
53. **Ezzedine K**, Heenen M, Malvy D. Imported cutaneous melioidosis in traveller, Belgium. *Emerg Infect Dis* 2007; 13: 946-7 (IF: 6.751, Rang SIGAPS A).
54. **Ezzedine K**, Rafii N, Heenen M. Lymphomatoid contact dermatitis to an exotic wood: a very harmful toilet seat. *Contact Dermatitis* 2007; 57: 128-30 (IF: 3.747, Rang SIGAPS B).
55. **Ezzedine K**, Malvy D. Recurrent bruising with immunological abnormalities in a 24-year-old traveller: a new entity? *J Eur Acad Dermatol Venereol* 2007; 21: 1448-50 (IF: 2.826, Rang SIGAPS B).
56. **Ezzedine K**, Dhaussy I, Malvy D, Laporte M, De Dobbeleer G, Heenen M. Long-term prurigo in a returned expatriate with chronic strongyloidiasis. *Int J Dermatol* 2006; 45: 1009-10 (IF: 1.312, Rang SIGAPS D).
57. **Ezzedine K**, Vadoud-Seyedi J, Heenen M. Nicolau syndrome following diclofenac administration. *Br J Dermatol* 2004; 150: 385-7 (IF: 4.275, Rang SIGAPS A).

REFERENCED PUBLICATIONS (REVIEWS AND EDITORIALS)

1. Rodrigues M, **Ezzedine K**, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. *J Am Acad Dermatol* 2017; 77: 1-13.
2. Rodrigues M, **Ezzedine K**, Hamzavi I, Pandya AG, Harris JE. Current and emerging treatments for vitiligo. *J Am Acad Dermatol* 2017; 77: 17-29.
3. ElBuluk N, **Ezzedine K**. Quality of Life/Burden of Disease in Vitiligo; Comorbidities/Systemic Effects. *Dermatol Clin* 2017 (in press)
4. Eleftheriadou V, **Ezzedine K**. Portable home phototherapy for vitiligo. *Clin Dermatol* 2016 (in press). (IF: 2.367, Rang SIGAPS C)
5. **Ezzedine K**, Silverberg N. A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children. *Pediatrics* 2016 (In press, IF: 5.473, Rang SIGAPS A)
6. Picardo M, Dell'Anna ML, **Ezzedine K**, Hamzavi I, Harris JE, Parsad D, Taieb A. Vitiligo. *Nature Reviews Disease Primers* 2015; 15011.
7. **Ezzedine K**, Eleftheriadou V, Whitton M, Nan Geel N. Vitiligo. *Lancet* 2015; 386: 74-84. (IF: 45.217, Rang SIGAPS A).
8. Hosseini M, **Ezzedine K**, Taieb A, Rezvani H. Nucleotide excision repair diseases: Oxidative and energy metabolism as a potential explanation underlying clinical heterogeneity. *J Invest Dermatol* 2015; 135: 341-51 (in press) (IF: 7.216, Rang SIGAPS A).
9. Taieb A, Alomar A, Böhm M, Dell'Anna ML, De Pase A, Eleftheriadou V, **Ezzedine K**, Gauthier Y, Gawkrödger DJ, Jouary J, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M. Guidelines for the Management of Vitiligo: the EDF consensus By the writing group of the Vitiligo European Task Force (VETF) in cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS). *Br J Dermatol* 2013; 168: 5-19 (IF: 4.275, Rang SIGAPS A).
10. Léauté-Labrèze C, Prey S, **Ezzedine K**. Infantile hemangioma : Part II. Risks, Complications and Treatment. *J Eur Acad Dermatol Venereol* 2011; 25: 1254-60 (IF: 2.826, Rang SIGAPS B).
11. Léauté-Labrèze C, Prey S, **Ezzedine K**. Infantile hemangioma : Part I. Pathophysiology, Epidemiology, Clinical features, Life cycle, and Associated structural abnormalities. *J Eur Acad Dermatol Venereol* 2011; 25: 1245-53 (IF: 2.826, Rang SIGAPS B).
12. Taieb A, Morice F, Jouary T, **Ezzedine K**, Cario-André M, Gauthier Y. Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: deriving a new scenario for common nonsegmental vitiligo. *Pigment Cell Melanoma Res*; 2008; 21: 646-52 (IF: 4.619, Rang SIGAPS B).
13. **Ezzedine K**, Pandya A. Time for a patient-oriented outcome in vitiligo: the vitiligo noticeability scale. *Br J Dermatol* 2016 (in press) (IF: 4.275, Rang SIGAPS A).
14. **Ezzedine K**, Barbarot S. Atopic dermatitis and type-1 diabetes mellitus: a true positive association? *Br J Dermatol* 2016; 174: 16. (IF: 4.275, Rang SIGAPS A).
15. **Ezzedine K**, Sheth V, Rodrigues M, Eleftheriadou V, Harris J, Hamzavi I, Pandya A. Vitiligo is not a cosmetic disease. *J Am Acad Dermatol* 2015; 73: 883-5. (IF: 4.449, Rang SIGAPS A).
16. Nijsten T, Apfelbacher C, Gisondi P, Silverberg J, Cohen A, Barbarot S, Wakkee M, **Ezzedine K**. Dermatoepidemiology; what's up people? *Br J Dermatol* 2015; 173: 881-3. (IF: 4.275, Rang SIGAPS A).
17. **Ezzedine K**, Barbarot S. Can we trust questions about self- and caregivers reported eczema in epidemiologic studies? *Br J Dermatol* 2015; 173: 1356-7. (IF: 4.275, Rang SIGAPS A).

1. Harris JE, Ezzedine K. Vitiligo. Fitzpatrick's Dermatology in General Medicine 9th Edition. (in press)
2. Taieb A, Morice-Picard F, **Ezzedine K**. Genetic disorders of pigmentation. In: **Rook's Textbook of Dermatology, Ninth Edition**. (T. Burns, S. Breathnach, N. Cox, C. Griffiths, éditeurs), ISBN: 978-1-118-44119-0, Wiley Blackwell Publishing Ltd, 2016.
3. Amiel A, **Ezzedine K**, Van De Leemput C. Influence du sentiment d'efficacité personnelle et des conditions matérielles sur les comportements d'évitement de la technologie dans le cadre de la préparation d'un examen de dermatologie. In C Van De Leemput, C Chauvin, & C Hellemans (Eds.), *Activités humaines, Technologies et Bien-être: Actes du Tème colloque de psychologie ergonomique Epique*, Paris: Arpege Science Publishing, 2013.
4. Valet F, **Ezzedine K**, Malvy D, Mary JY, Guinot C. Quality assessment of ordinal scales depicting skin ageing severity. In: **Textbook of Aging Skin**. (M. A. Farage, K. W. Miller et H. I. Maibach, éditeurs), ISBN 978-3-540-89655-5 (Print) and ISBN 978-3-540-89656-2 (Electronic publication), Springer-Verlag Berlin Heidelberg, 2010, pp 921-8.
5. **Ezzedine K**, Lepreux S, Taieb A. Vitiligo and immunodeficiency. Dans : **Textbook of Vitiligo**. (M. Picardo, A. Taieb Editeurs), ISBN 978-3-540-69360-4 (Print) and ISBN 978-3-540-69361-1 (Electronic publication), Springer-Verlag Berlin Heidelberg, 2010, pp 91-7.
6. **Ezzedine K**, Seneschal J, Attili R, Taieb A. Inflammatory vitiligo. Dans : **Textbook of Vitiligo**. (M. Picardo, A. Taieb Editeurs), ISBN 978-3-540-69360-4 (Print) and ISBN 978-3-540-69361-1 (Electronic publication), Springer-Verlag Berlin Heidelberg, 2010, pp 99-105.
7. Amiel A, Van De Leemput C, Schietse B, **Ezzedine K**. Effet de la familiarisation sur l'évolution des perceptions d'utilité et d'utilisabilité d'une plateforme web de dermatologie. In : **N. Pettersen, J.-S. Boudrias & A. Savoie (Eds.), Entre tradition et Innovation, comment transformons-nous l'univers du travail ?** Québec: Presses de l'Université du Québec, ISBN 978-2-7605-1530-7, 2008.
8. Amiel A, Van De Leemput C, Schietse B, **Ezzedine K**. Approche différentielle des performances lors de tests d'utilisabilité: étude de l'influence de variables culturelles et contextuelles. 5èmes Journées d'Étude en Psychologie Ergonomique – EPIQUE (28-30 Septembre 2008, Nice, France), 2008, **Actes du Colloque EPIQUE**, Paris: Arpege Science Publishing, 2008, pp.24-31.